Report copyright - Scrip · garding Celgene’s long-term revenue pros-pects,” William Blair analyst Matt Phipps said in a Jan. 3 note, pointing out that Revlimid is the biggest uncertainty going
Please pass captcha verification before submit form
Please pass captcha verification before submit form